PROS1 and infection: Previous pseudovirus studies reported that nafamostat mesylate inhibits SARS-CoV-2 S protein mediated entry into Calu-3 cells with ∼15-fold higher efficiency than that of camostat mesylate, and that nafamostat blocks infection by authentic SARS-CoV-2 more effectively than camostat in these cells (14).